Novel Gene Therapies to Mitigate Neurotoxicity for Improved Treatment of Neurodegenerative Disease


Executive Summary


Dysfunction of the kynurenine pathway has been linked to Parkinson’s disease, Alzheimer’s disease, ALS, Huntington’s disease, brain ischemia, CNS infections, autoimmune disorders, mood disorders, and schizophrenia. If this pathway could be manipulated neuroprotection could be achieved. 


Description of Technology


MSU researchers have developed a variety of gene therapy vectors to manipulate the kynurenine pathway. This novel technology utilizes adeno-associated viral vectors to overexpress an kynurenine pathway-modulating enzyme in a cell-specific manner in various cell populations in the brains. This involves using novel viral vectors that are designed to divert the kynurenine pathway into a neuroprotective mode. This approach thus provides a potential neurorestorative and/or neuroprotective environment.


Key Benefits

  • Neuroprotectant for a plethora of neurological disorders
  • Cell Specific Targeting: Unique library of viral vectors aims at precisely targeting specific cells
  • Modulating a normal cellular pathway, thus, no ectopic genes will be expressed.



  • Treatment of multiple neurodegenerative diseases
  • Personalized medicine: Ability to treat patients based on their individual disease


Patent Status: 


Under review 


Licensing Rights Available


Full licensing rights available


Inventors: Fredric Manfredsson, Lena Brundin


Tech ID: TEC2015-0048


Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email:, phone (direct): (517)884-1829. 


Patent Information:


For Information, Contact:

Anupam Jhingran
Technology Manager
Michigan State University